| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Faeth Therapeutics, Inc. Common Stock$24
+0.81 (+3.49%)
Market Cap
-
EPS
-
P/E Ratio
-
Value Trade
-
%
Week
%
1 Month
%
3 Month
%
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
140.31 K
52 Week Range
-
% held by Insiders
7.38 %
% held by Institutions
99.47 %
Enterprise Value
-
Total Shares
-
Short %
64.38 %
Float Shares
-
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in FTH
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Faeth Therapeutics, Inc. Common Stock (FTH) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
FTH
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
FTH
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
FTH
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
FTH Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
FTH Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-FTH
Jun 15, 2026Sensei Biotherapeutics Announces Name Change to Faeth Therapeutics, Focused on Advancing PIKTOR, an Oral Therapy Targeting One of the Most Frequently Altered Pathways in Cancer - Stockholders approved conversion of the S
Sensei Biotherapeutics has officially changed its corporate name to Faeth Therapeutics, with new trading under the ticker FTH beginning June 16, 2026. The company is advancing PIKTOR, an oral therapy targeting the PI3K/AKT/mTOR pathway, aiming for Phase 2 data in advanced endometrial cancer by the latter half of 2026. The leadership team has been strengthened with new appointments to guide the company through upcoming clinical trials. This pivot follows stockholder approval of a significant private placement, providing the necessary funding for these initiatives.
Read more →-FTH
May 21, 2026SENSEI BIOTHERAPEUTICS, INC. UNAUDITED PRO FORMA CONDENSED FINANCIAL INFORMATION On
On February 17, 2026, Sensei Biotherapeutics, Inc. completed the acquisition of Faeth Holdings Therapeutics, Inc. and its subsidiary, which is expected to enhance its operational capabilities. Concurrently, the company raised $200 million in gross proceeds through a Securities Purchase Agreement with investors. The issuance of Series B Preferred Stock is set to convert into common stock following stockholder approval scheduled for June 10, 2026. The company provided unaudited pro forma condensed financial information reflecting the anticipated changes from these transactions.
Read more →-FTH
May 15, 2026Sensei Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update First patient dosed in Phase 1b/2 trial of PIKTOR in HR+/HER2- advanced breast cancer Topline Phase 2 data in patients wit
Sensei Biotherapeutics has reported its financial results for the first quarter of 2026, highlighting the dosing of the first patient in a Phase 1b/2 trial of the cancer therapy PIKTOR. The company has acquired Faeth Therapeutics, enabling enhanced capital and progress towards clinical milestones. Despite a significant net loss of $170.2 million and increased research expenses, management is optimistic about the potential of PIKTOR in treating advanced cancers.
Read more →-FTH
Mar 30, 2026Sensei Biotherapeutics Reports Full Year 2025 Financial Results and Provides Corporate Update Faeth acquisition adds PIKTOR, an all-oral combination product candidate targeting multiple nodes of the PI3K/AKT/mTOR pathway
Sensei Biotherapeutics reported its financial results for the year ended December 31, 2025, highlighting the acquisition of Faeth Therapeutics and the associated $200 million private placement to support the development of PIKTOR. This investigational product aims to target multiple nodes of the PI3K/AKT/mTOR pathway in treatments for endometrial and breast cancer. While the company's R&D expenses decreased, they still reported a net loss of $21.1 million, though improved from the previous year's loss. The company remains focused on advancing PIKTOR through key clinical milestones expected by the end of 2026.
Read more →-FTH
Feb 18, 2026Sensei Biotherapeutics Announces Acquisition of Faeth Therapeutics and $200 Million Concurrent Private Placement Acquisition of Faeth and concurrent $200 million private investment positions the combined company to advan
Sensei Biotherapeutics has announced its acquisition of Faeth Therapeutics, alongside a concurrent $200 million private placement. This strategic move is aimed at enhancing Sensei's pipeline, particularly with PIKTOR, a multi-node inhibitor designed to target solid tumors like endometrial and breast cancer. The funding will primarily support key clinical trials, including an ongoing Phase 2 trial for advanced endometrial cancer. Additionally, the acquisition is structured as a stock-for-stock transaction, significantly changing the equity landscape of Sensei post-acquisition.
Read more →-FTH
Nov 14, 2025Sensei Biotherapeutics Reports Third Quarter 2025 Financial Results BOSTON, MA
Sensei Biotherapeutics reported its financial results for Q3 2025, highlighting the discontinuation of its lead product, solnerstotug. The company is currently exploring strategic alternatives, which may involve asset sales or a potential merger, while reducing its workforce by 65%. A review of the company's development pipeline has led to this decision amid unfavorable market conditions, resulting in a notable decrease in cash and substantial net losses. The company's cash and cash equivalents dropped significantly to $25 million, raising concerns about its financial viability.
Read more →-FTH
Oct 30, 2025Sensei Biotherapeutics Announces Initiation of Strategic Review to Maximize Shareholder Value BOSTON
Sensei Biotherapeutics has announced the discontinuation of its solnerstotug development and is initiating a strategic review to explore alternatives for maximizing shareholder value. The company is considering several options, including asset sales, licensing, or potential mergers while planning a significant workforce reduction. The decision follows a careful evaluation of the company's pipeline and market conditions, and the future of its ongoing clinical trials now hangs in the balance.
Read more →-FTH
Oct 17, 2025Sensei Biotherapeutics Reports New Clinical Results Highlighting Durable Progression Free Survival Data for Solnerstotug in PD-(L)1 Resistant Tumors at the ESMO Congress 2025 - 6-month progression-free survival (PFS) of
Sensei Biotherapeutics has reported promising clinical results for solnerstotug in PD-(L)1 resistant tumors at the ESMO Congress 2025. A 50% 6-month progression-free survival rate was observed in the 15 mg/kg cohort, significantly higher than historical rates for similar treatments. The drug demonstrated a favorable safety profile, with mild cytokine release syndrome reported. Plans for Phase 2 trials are underway to further evaluate solnerstotug's efficacy in Non-Small Cell Lung Cancer and Merkel Cell Carcinoma.
Read more →-FTH
Aug 5, 2025Sensei Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update - Full data for Phase 1/2 dose expansion cohort expected by year-end 2025 - - Cash runway into the second quarter of 2026
Sensei Biotherapeutics reported its financial results for Q2 2025, highlighting a transition in its phase 1/2 study of solnerstotug towards data expected by year-end 2025. The company noted a favorable safety profile for solnerstotug, particularly in combination with cemiplimab. Financially, Sensei has sufficient cash to fund operations into Q2 2026, although it faced a net loss of $4.9 million. The firm plans to advance multiple Phase 2 studies to target PD-(L)1 resistant tumors, aiming to tap into significant market opportunities.
Read more →-FTH
May 6, 2025Sensei Biotherapeutics Reports First Quarter 2025 Financial Results and Updates on Clinical Progress - Favorable clinical data in PD-(L)1 resistant patients - - Dose expansion enrollment complete with full data expected
Sensei Biotherapeutics has reported its financial results for the first quarter of 2025, indicating a significant quarter with favorable clinical data for its treatment targeting PD-(L)1-resistant cancer patients. The company has successfully completed enrollment for its dose expansion phase, anticipating full data release by the end of 2025. Despite a decrease in R&D expenses and an extended cash runway, the company continues to face challenges with net losses and inherent uncertainties in clinical development.
Read more →-FTH
Mar 28, 2025Sensei Biotherapeutics Reports Full Year 2024 Financial Results and Update on Clinical Progress - Preliminary efficacy data from Phase 1/2 dose expansion cohort show durable responses and tumor shrinkage in a PD-(L)1 res
Sensei Biotherapeutics announced their financial results for 2024, highlighting encouraging preliminary efficacy data from their Phase 1/2 trial of solnerstotug, especially in PD-(L)1 resistant tumors. The company achieved its target enrollment for the dose expansion cohort, with final data expected by the end of 2025. Despite showing clinical potential, Sensei reported a net loss of $30.2 million for the year, a slight improvement over the previous year's loss. They also stated their financial resources are expected to support operations into the second quarter of 2026.
Read more →-FTH
Mar 27, 2025Sensei Biotherapeutics Reports Favorable Preliminary Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors Initial clinical activity in a PD-(L)1 resistant population, with an ORR almost three times higher tha
Sensei Biotherapeutics announced favorable preliminary data on its Phase 1/2 trial of solnerstotug for patients with PD-(L)1 resistant tumors. The treatment showed an overall response rate (ORR) of 14%, significantly higher than the historical 5% rate for re-treatment, and included cases of durable responses in patients with Merkel Cell Carcinoma and microsatellite instability-high colorectal cancer. The drug appears well-tolerated with mild, manageable side effects. A Phase 2 trial is anticipated to begin in Q1 2026, pending funding.
Read more →-FTH
Nov 14, 2024Sensei Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights - SNS-101 Phase 1/2 dose expansion clinical data expected in the first half of 2025 - - Organizational restructuring to f
Sensei Biotherapeutics has reported financial results for the third quarter of 2024, highlighting significant progress in patient enrollment for the SNS-101 Phase 1/2 clinical trial. To refocus efforts on clinical development, the company is undergoing organizational restructuring, including reducing its workforce. The cash runway has been extended to the second quarter of 2026, allowing more time for the advancing clinical studies. SNS-101 aims to target the immune checkpoint VISTA, with the potential for treatment across various cancer indications.
Read more →-FTH
Aug 6, 2024Sensei Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights - Promising Phase 1/2 SNS-101 clinical data presented at ASCO 2024 - - Enrollment in the Phase 1 dose expansion of SNS-1
Sensei Biotherapeutics reported its second quarter 2024 financial results and highlighted recent developments in its clinical trials. The company presented promising Phase 1/2 data for SNS-101 at ASCO 2024, demonstrating early signs of activity in a typically resistant patient population. Sensei's financial health is robust with a cash runway extending into the fourth quarter of 2025, allowing for continued development of its therapies. However, the company also noted a net loss of $7.1 million and an overall increase in R&D expenses as it advances its clinical trials.
Read more →-FTH
Jun 3, 2024Disclaimer This presentation has been prepared by Sensei Biotherapeutics, Inc. (the "Company," "we," "us") and is made for informational purposes only. The information set forth herein does not purport to be complete or
Sensei Biotherapeutics has released a corporate deck detailing their innovative drug development and ongoing clinical trials, focusing on SNS-101, their lead asset targeting the VISTA checkpoint. The presentation highlights the potential therapeutic benefits and safety profile of SNS-101, which is currently in a Phase 1b study. The company believes it has sufficient funding to support operations through the middle of 2025 and has plans for initial data release by the end of 2024. However, the company acknowledges inherent uncertainties and risks associated with clinical trial outcomes and market estimates.
Read more →-FTH
May 23, 2024Sensei Biotherapeutics Presents Promising Clinical Data from Phase 1 Dose Escalation Study of SNS-101 - Once every 3-week dosing of SNS-101 demonstrates initial signs of promising clinical activity - - Pharmacokinetic an
Sensei Biotherapeutics has presented promising data from its Phase 1 dose escalation study of SNS-101, a monoclonal antibody targeting the immune checkpoint VISTA. Preliminary results indicate that SNS-101 is well-tolerated, with no dose-limiting toxicities and initial signs of clinical activity observed in patients with advanced solid tumors. Additionally, the drug has shown a favorable pharmacokinetic profile, reinforcing its potential effectiveness. The study continues with ongoing patient enrollment and is expected to yield further data by the end of 2024.
Read more →-FTH
May 9, 2024Sensei Biotherapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights - Completed SNS-101 monotherapy and combination dose escalation through 15mg/kg with no dose limiting toxicities - - Comp
Sensei Biotherapeutics has reported its first quarter 2024 financial results, highlighting the completion of SNS-101 dose escalation studies, which showed no dose limiting toxicities. The company plans to present topline clinical data at the 2024 ASCO Annual Meeting and is advancing patient enrollment for dose expansion studies. Despite a current cash runway into the fourth quarter of 2025, Sensei experienced a net loss of $8.0 million for the quarter, reflecting ongoing operational costs in a competitive market.
Read more →-FTH
Feb 28, 2024Sensei Biotherapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights - Updated dose escalation data from SNS-101 clinical study supports favorable and potentially best-in-class safety and PK pro
Sensei Biotherapeutics reported its financial results for 2023, highlighting the progress of its lead product, SNS-101, in clinical development. Recent data suggests the therapy supports favorable safety and pharmacokinetics, with topline efficacy and biomarker data expected in Q2 2024. The company reported a net loss of $34.1 million for the year, which is lower than in 2022, and stated that its cash reserves should fund operations into Q4 2025. Sensei continues to advance its clinical pipeline, focusing on next-generation therapeutics for cancer treatment.
Read more →-FTH
Nov 7, 2023Sensei Biotherapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights - SNS-101 initial Phase 1 clinical data presented at SITC demonstrate potential best-in-class safety and pharmacokinetic
Sensei Biotherapeutics reported its third quarter 2023 financial results, highlighting significant progress in its clinical trial for SNS-101. The initial Phase 1 clinical data suggest this investigational candidate could have a best-in-class safety profile with no reported cytokine release syndrome. The company is on track with its trial enrollment and anticipates further clinical data during 2024. However, its net loss has decreased from the previous year, but the company has also seen a decline in its cash reserves since the end of 2022.
Read more →-FTH
Nov 3, 2023Sensei Biotherapeutics Reports Favorable Clinical Data for SNS-101 at 2023 SITC Annual Meeting - Clinical dose escalation data for SNS-101 monotherapy show well tolerated safety profile, potentially best-in-class pharmac
Sensei Biotherapeutics revealed promising clinical data for SNS-101 at the 2023 SITC Annual Meeting. The Phase 1/2 trial data shows that the VISTA-blocking antibody has a well-tolerated safety profile and potentially superior pharmacokinetics compared to first-generation VISTA antibodies. The preliminary results suggest that SNS-101 could effectively elicit immune-mediated anti-tumor activity while mitigating the risks encountered by previous therapies. Further data, including efficacy analysis, is expected in 2024.
Read more →-FTH
Aug 3, 2023Sensei Biotherapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights Phase 1/2 clinical trial enrolling for lead investigational candidate SNS-101, a conditionally active VISTA- blocking an
Sensei Biotherapeutics announced its financial results for the second quarter of 2023, highlighting progress in the Phase 1/2 clinical trial for its lead candidate SNS-101, aimed at treating advanced solid tumors. Six patients have been enrolled thus far, with initial pharmacokinetic and safety data expected by the end of 2023. The company reported a net loss of $9.4 million for the quarter, compared to $10.5 million in the same period last year, while maintaining a cash runway anticipated to extend into the second half of 2025. Additionally, Sensei appointed Dr. Robert Schreiber as Chair of its Immuno-Oncology Advisory Board to bolster the candidate's development efforts.
Read more →-FTH
May 9, 2023Sensei Biotherapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights - Investigational New Drug (IND) application for SNS-101 cleared by U.S. Food and Drug Administration (FDA) with first pa
Sensei Biotherapeutics has reported its financial results for Q1 2023, highlighting the FDA's clearance of their IND application for SNS-101, which will enter Phase 1/2 trials targeting advanced solid tumors. The company has noted a strong balance sheet, with a cash runway extending into the second half of 2025, and a reduction in R&D expenses. Additionally, Sensei's collaboration efforts and ongoing development of other pipeline candidates, including SNS-102 and SNS-103, were emphasized as key advances in their immuno-oncology initiatives.
Read more →-FTH
Mar 28, 2023Sensei Biotherapeutics Reports Full Year 2022 Financial Results and Recent Business Highlights - Investigational New Drug (IND) application submitted for lead candidate SNS-101, a conditionally active VISTA-blocking anti
Sensei Biotherapeutics has announced its full-year 2022 financial results, highlighting the submission of an Investigational New Drug (IND) application for their lead candidate SNS-101, an antibody targeting the immune checkpoint VISTA. The company has formed strategic collaborations with notable institutions to further the development of SNS-101. Financial results show a decline in cash reserves alongside an increased net loss. However, the company maintains a robust cash position expected to extend operations into the second half of 2025 while advancing other therapeutic candidates through its TMAb platform.
Read more →-FTH
Mar 7, 2023Sensei Biotherapeutics Adopts Stockholder Rights Agreement BOSTON, MA
Sensei Biotherapeutics has adopted a limited duration stockholder rights agreement to safeguard stockholder interests and enhance value. This agreement reduces the likelihood of hostile takeovers by allowing the Board sufficient time to respond to potential control attempts. The rights will be issued as a dividend to stockholders and will last until March 7, 2024, unless replaced or revoked sooner. The move positions the Board to make informed decisions on ownership changes affecting Sensei.
Read more →-FTH
Feb 6, 2023Sensei Biotherapeutics Signs Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) to Expand Development Plan for SNS-101, a Conditionally Active VISTA-blocking Antibody BOSTON
Sensei Biotherapeutics has signed a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) to broaden the research and development plan for SNS-101, a VISTA-blocking antibody. This collaboration seeks to enhance understanding of VISTA's role in immune checkpoint resistance and explore SNS-101's combination therapy potential. An Investigational New Drug (IND) application is expected to be submitted by April 2023, with trials projected to start later in the year, pending regulatory approval. The agreement aims to bolster Sensei’s clinical development strategy for SNS-101.
Read more →-FTH
Dec 8, 2022Sensei Biotherapeutics Provides Update on Strategic Priorities - Closes Boston research site, reducing workforce by approximately 40 percent to decrease operating expenses - - Continued focus on development of TMAb progr
Sensei Biotherapeutics Provides Update on Strategic Priorities - Closes Boston research site, reducing workforce by approximately 40 percent to decrease operating expenses - - Continued focus on development of TMAb programs; IND submission for lead antibody SNS-101 anticipated
Read more →-FTH
Nov 10, 2022Sensei Biotherapeutics Presents Preclinical Data at the 37 th Society for Immunotherapy of Cancer (SITC) Annual Meeting - SNS-101, a highly pH-selective antibody to VISTA, demonstrated anti-tumor effects and promising ph
Sensei Biotherapeutics Presents Preclinical Data at the 37th Society for Immunotherapy of Cancer (SITC) Annual Meeting - SNS-101, a highly pH-selective antibody to VISTA, demonstrated anti-tumor effects and promising pharmacokinetic properties in preclinical studies - - Charac
Read more →-FTH
Nov 8, 2022Sensei Biotherapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights - Recent SNS-101 preclinical data demonstrate a favorable pharmacokinetic profile, evidence of advanced anti-tumor effect
Sensei Biotherapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights - Recent SNS-101 preclinical data demonstrate a favorable pharmacokinetic profile, evidence of advanced anti-tumor effects and a superior cytokine release profile - - New preclin
Read more →-FTH
Sep 30, 2022Sensei Biotherapeutics Presents Preclinical Data for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Sixth Annual CRI-ENCI-AACR International Cancer Immunotherapy Conference: Translating Science into Surv
Sensei Biotherapeutics Presents Preclinical Data for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Sixth Annual CRI-ENCI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival - SNS-101 demonstrated a favorable pharmacokinetic pr
Read more →-FTH
Aug 31, 2022Sensei Biotherapeutics Announces New Preclinical Data Demonstrating Favorable Pharmacokinetic and Immunologic Effects of SNS-101, a pH-selective VISTA-blocking Antibody BOSTON, MA
Sensei Biotherapeutics Announces New Preclinical Data Demonstrating Favorable Pharmacokinetic and Immunologic Effects of SNS-101, a VISTA-blocking Antibody BOSTON, MA August 31, 2022 Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immuno-oncology company focused on the discove
Read more →-FTH
Aug 9, 2022Sensei Biotherapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights - SNS-101 pre-IND feedback received from FDA with program on track for IND filing in first half of 2023 - - New SNS-101
Sensei Biotherapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights - SNS-101 pre-IND feedback received from FDA with program on track for IND filing in first half of 2023 - - New SNS-101 single dose pharmacokinetic data in non-human primates t
Read more →-FTH
May 10, 2022Sensei Biotherapeutics Reports First Quarter 2022 Financial Results and Recent Business Highlights - SNS-101 preclinical data provide encouraging validation of pH-sensitive approach to inhibiting VISTA with high selectiv
Sensei Biotherapeutics Reports First Quarter 2022 Financial Results and Recent Business Highlights - SNS-101 preclinical data provide encouraging validation of pH-sensitive approach to inhibiting VISTA with high selectivity to treat solid tumors - Cash runway extended into the
Read more →-FTH
Apr 20, 2022Robert Pierce, MD World Vaccine Congress 2022 Washington, DC SNS-101, A Unique Tumor-selective Anti-VISTA Monoclonal Antibody with a Novel Mechanism of Action Disclaimer This presentation has been prepared by Sensei Biot
Robert Pierce, MD World Vaccine Congress 2022 Washington, DC SNS-101, A Unique Tumor-selective Anti-VISTA Monoclonal Antibody with a Novel Mechanism of Action Disclaimer This presentation has been prepared by Sensei Biotherapeutics, Inc. (the Company, we, us ) and is made for i
Read more →-FTH
Mar 10, 2022Sensei Biotherapeutics Reports Full Year 2021 Financial Results and Business Highlights - Reported preclinical proof of concept data from TMAb platform demonstrating potent and selective pH-dependent binding to active VI
Sensei Biotherapeutics Reports Full Year 2021 Financial Results and Business Highlights - Reported preclinical proof of concept data from TMAb platform demonstrating potent and selective pH-dependent binding to active VISTA - - Initiated 2 new therapeutic programs and IND-ena
Read more →-FTH
Mar 9, 2022Sensei Biotherapeutics Appoints William Ringo, MBA, as Chair of Board of Directors - Brings decades of both board and management life sciences experience BOSTON, MA
Sensei Biotherapeutics Appoints William Ringo, MBA, as Chair of Board of Directors - Brings decades of both board and management life sciences experience BOSTON, MA March 9, 2022 Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immunotherapy company focused on the discovery and
Read more →-FTH
Jan 10, 2022Training the Immune System to Fight Cancer John K. Celebi, MBA President & Chief Executive Officer JP Morgan Healthcare Conference
Training the Immune System to Fight Cancer John K. Celebi, MBA President & Chief Executive Officer JP Morgan Healthcare This presentation has been prepared by Sensei Biotherapeutics, Inc. (the Company, we, us ) and is made for informational purposes only. The information set fo
Read more →-FTH
Dec 6, 2021This presentation has been prepared by Sensei Biotherapeutics, Inc. (the "Company," "we," "us") and is made for informational purposes only. The information set forth herein does not purport to be complete or to contain
August 4, 2021 Training the Immune System to Fight Cancer December 6, 2021 Exhibit 99.1 This presentation has been prepared by Sensei Biotherapeutics, Inc. (the "Company," "we," "us") and is made for informational purposes only. The information set forth herein does not purpor
Read more →-FTH
Nov 16, 2021VISTA Science Symposium
Presenters: Guest Speaker: John Celebi Prof. Robert Schreiber Chief Executive Officer Andrew M. Bursky and Jane M. Bursky Distinguished Professor of Pathology and Immunology, Professor of Molecular Microbiology and co-leader of the tumor Dr. Robert Pierce immunology program at t
Read more →-FTH
Nov 9, 2021Sensei Biotherapeutics Reports Third Quarter 2021 Results and Recent Business Highlights - SNS-101 identified as a tumor-selective anti-VISTA antibody product candidate from TMAb platform - - SNS-101 preclinical data acc
Sensei Biotherapeutics Reports Third Quarter 2021 Results and Recent Business Highlights - SNS-101 identified as a tumor-selective anti-VISTA antibody product candidate from TMAb platform - - SNS-101 preclinical data accepted for presentation at the Society for Immunotherapy of
Read more →-FTH
Aug 4, 2021Sensei Biotherapeutics Reports Second Quarter 2021 Results and Highlights Recent In Vivo Data from SNS-VISTA Program - Company announced first set of pH-sensitive anti-VISTA antibodies showing significant in vivo anti- t
Sensei Biotherapeutics Reports Second Quarter 2021 Results and Highlights Recent In Vivo Data from SNS-VISTA Program - Company announced first set of pH-sensitive anti-VISTA antibodies showing significant in vivo anti- tumor activity in combination with PD-1 blockade in a huma
Read more →-FTH
Jun 28, 2021Sensei Biotherapeutics Announces Prioritization of Next-Generation Multi-Antigenic ImmunoPhage Platform, Monoclonal Antibody and Nanobody Programs - Company to focus on development of next-generation phage product candid
Sensei Biotherapeutics Announces Prioritization of Next-Generation Multi-Antigenic ImmunoPhage Platform, Monoclonal Antibody and Nanobody Programs - Company to focus on development of next-generation phage product candidates from ImmunoPhage platform and monoclonal antibody an
Read more →-FTH
May 12, 2021Sensei Biotherapeutics Reports First Quarter 2021 Results and Provides Business Update - ImmunoPhage platform programs and the VISTA program continue to advance - - New safety and efficacy data from ongoing Phase 1/2 com
Sensei Biotherapeutics Reports First Quarter 2021 Results and Provides Business Update - ImmunoPhage platform programs and the VISTA program continue to advance - - New safety and efficacy data from ongoing Phase 1/2 combination study of SNS-301 in squamous cell carcinoma of t
Read more →-FTH
Apr 5, 2021Sensei Biotherapeutics Appoints Jessie M. English, Ph.D. to its Board of Directors Entrepreneurial leader brings expertise growing biotech platform companies BOSTON, MA and ROCKVILLE, MD
Sensei Biotherapeutics Appoints Jessie M. English, Ph.D. to its Board of Directors Entrepreneurial leader brings expertise growing biotech platform companies BOSTON, MA and ROCKVILLE, MD April 5, 2021 Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), a clinical-stage immunotherapy
Read more →-FTH
Mar 25, 2021Sensei Biotherapeutics Reports Full Year 2020 Results and Provides Business Update -Successfully completed upsized IPO in February 2021 raising approximately $152.6 million in gross proceeds -Large subset of data expecte
Sensei Biotherapeutics Reports Full Year 2020 Results and Provides Business Update -Successfully completed upsized IPO in February 2021 raising approximately $152.6 million in gross proceeds -Large subset of data expected from ongoing Phase 1/2 study of SNS-301 in combination w
Read more →-FTH
Feb 10, 2021Sensei Biotherapeutics Announces Closing of Initial Public Offering BOSTON, MA and ROCKVILLE, MD
Sensei Biotherapeutics Announces Closing of Initial Public Offering BOSTON, MA and ROCKVILLE, MD February 10, 2021 Sensei Biotherapeutics, Inc., a clinical-stage immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today ann
Read more →Competitive Position
How FTH ranks across every disease it competes inCompetitive Position is a premium feature
See how FTH ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial